Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Revenue history
Currency unavailable · from the income statement
No Revenue data reported for this period type.
Revenue vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $1.14B USD | +185.8% | +35.2% | |
| LTM Mar 2026 | $360.78M USD | +21.2% | +51.8% | |
| LTM Mar 2026 | $117.05M USD | +16.3% | +4.5% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 1.33M SEK | -57.1% | — |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — |
| Peer median (excluding AVLN) | — | +18.8% | +35.2% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.